EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Size-Based Targeting of Anti-Inflammatory Nanoparticles for Drug Delivery to Blast-Injured BBB for TBI Treatment

Rebecca R. Schmitt, Sonali Garg, Tracey A. Ignatowski, Kathiravan Kaliyappan, Vijaya Prakash Krishnan Muthaiah, Paras N. Prasad, Supriya D. Mahajan

Immuno · 20.04.2026 · 6 (2) · 29

DOI: 10.3390/immuno6020029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno, online erschienen am 20.04.2026. Verfasst von Rebecca R. Schmitt und 6 weiteren Autor:innen. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University at Buffalo Office of Vice President for Research, Innovation and Economic Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide, with blast TBI (bTBI) particularly affecting military personnel and individuals exposed to explosive environments, yet there are no available curative treatments to date. While adrenergic receptor antagonists have shown promise in reducing neuroinflammation and improving TBI mortality rates, systemic administration of these drugs can have deleterious effects including bradycardia and hypotension. Here, we introduce a polymeric nanoparticle system for the delivery of adrenergic receptor antagonists, which allows for size-based targeting of the injured blood–brain barrier (BBB). These nanoparticles consist of chitosan-coated polylactic co-glycolic acid encapsulating the β-adrenergic receptor antagonist propranolol and/or the α-adrenergic receptor antagonist phenoxybenzamine. Particles designed with a 200 nm hydrodynamic diameter showed a 20–24% increase in permeability on an in vitro contact co-culture BBB model exposed to a 23 or 35 PSI acoustic blast when compared to uninjured controls, whereas 100 nm particles show no difference, suggesting blast injury induces BBB damage that enables the accumulation of larger particles. Treatment of blast-injured human brain microvascular cells with our nanoformulation reduced extracellular inflammatory cytokine levels and reduced the expression of pro-inflammatory markers in microglia. Moreover, these particles mitigated the upregulation of extracellular TNFα induced by free phenoxybenzamine in injured and uninjured microglia, suggesting nanoparticle drug encapsulation can reduce adverse drug reactions in the brain. Together, these findings provide proof-of-concept for size-based targeting and the potential anti-inflammatory effects of CS-PLGA nanoparticles containing adrenergic receptor antagonists for treatment of TBI and bTBI.

Förderung

  • University at Buffalo Office of Vice President for Research, Innovation and Economic Development

Zitieren

APA

Schmitt, R. R., Garg, S., Ignatowski, T. A., Kaliyappan, K., Muthaiah, V. P. K., Prasad, P. N., & Mahajan, S. D. (2026). Size-Based Targeting of Anti-Inflammatory Nanoparticles for Drug Delivery to Blast-Injured BBB for TBI Treatment. Immuno, 6(2), 29. https://doi.org/10.3390/immuno6020029

Vancouver

Schmitt RR, Garg S, Ignatowski TA, Kaliyappan K, Muthaiah VPK, Prasad PN, et al. Size-Based Targeting of Anti-Inflammatory Nanoparticles for Drug Delivery to Blast-Injured BBB for TBI Treatment. Immuno. 2026;6(2):29. doi:10.3390/immuno6020029

BibTeX
@article{Schmitt2026,
  author = {Schmitt, Rebecca R. and Garg, Sonali and Ignatowski, Tracey A. and Kaliyappan, Kathiravan and Muthaiah, Vijaya Prakash Krishnan and Prasad, Paras N. and Mahajan, Supriya D.},
  title = {Size-Based Targeting of Anti-Inflammatory Nanoparticles for Drug Delivery to Blast-Injured BBB for TBI Treatment},
  journal = {Immuno},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {29},
  doi = {10.3390/immuno6020029}
}
Kostenlos starten →